Background: Tenofovir diphosphate (TFV-DP) in red blood cells (measured in DBS) is a strong marker of cumulative adherence to tenofovir disoproxil fumarate/emtricitabine (TDF-FTC) and highly predictive of PrEP efficacy. However, because of its long half-life, TFV-DP does not discriminate recent vs. remote dosing. FTC is phosphorylated to FTC-triphosphate (FTC-TP) in red blood cells, which is simultaneously measured with TFV-DP in DBS, but the half-life and clinical utility of FTC-TP have not been elucidated. We aimed to determine the half-life of FTC-TP in DBS and to evaluate its utility as a marker of recent dosing.
Methods: DBS were collected from 13 HIV-negative and 10 HIV-infected adults participating in an intensive pharmacokinetic (PK) study of daily TDF-FTC for 30 days in HIV-negative individuals and 60 days in HIV-infected subjects. DBS were obtained following dosing on days 1, 3, 7, 20, 30 and 60 in all participants and also on days 35 and 45 (off drug) in the HIV-negative group. FTC-TP was extracted from a 3mm punch and quantified using LC-MS/MS with a lower limit of quantification (LLOQ) of 0.1 pmol/punch. Plasma TFV-FTC was quantified using LC-MS/MS with a LLOQ of 10 ng/ml. The FTC-TP half-life was determined using one-compartment first-order PK. To assess the effectiveness of FTC-TP as a marker of recent dosing, the concordance of FTC-TP in DBS with TFV-FTC in plasma was determined by comparing paired plasma/DBS samples collected at various study visits from participants receiving daily TDF-FTC in the iPrEx Open Label Extension (iPrEx OLE). Data are presented as median (range).
Results: Following dosing, FTC-TP reached Cmax at 4 (2-8) hours and exhibited a half-life of 31 (22-52) hours, with no difference according to HIV status (p=0.43). The FTC-TP average concentration at steady state was 0.25 (0.16-0.37) pmol/punch. A total of 482/515 (94%) paired plasma/DBS samples from iPrEX OLE were concordant for detection/non-detection of TFV/FTC in plasma vs. FTC-TP in DBS. When TFV/FTC were BLQ in plasma, FTC-TP was BLQ in DBS 98% of the time. When TFV/FTC were quantifiable in plasma, FTC-TP was quantifiable in DBS 90% of the time.
Conclusions: FTC-TP has a 31 hour half-life in DBS (compared with 17 days for TFV-DP). Excellent concordance (94%) was observed between detection of FTC-TP in DBS with detection of TFV/FTC in plasma, demonstrating that FTC-TP informs recent TFV/FTC dosing, thereby complimenting the long-term cumulative adherence measure provided by TFV-DP.